Non-Hodgkin’s Lymphomas in Children: 25-Year Clinical Experience

TT Valiev, AV Popa, AS Levashov, ES Belyaeva, NS Kulichkina, BV Kurdyukov, RS Ravshanova, GL Mentkevich

Scientific Research Institute of Pediatric Oncology and Hematology, NN Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478

For correspondence: Timur Teimurazovich Valiev, DSci, 24 Kashirskoye sh., Moscow, Russian Federation, 115478; Tel: +7(499)324-98-69; e-mail: timurvaliev@mail.ru

For citation: Valiev TT, Popa AV, Levashov AS, et al. Non-Hodgkin’s Lymphomas in Children: 25-Year Clinical Experience. Clinical oncohematology. 2016;9(4):420–37 (In Russ).

DOI: 10.21320/2500-2139-2016-9-4-420-437


ABSTRACT

Background & Aims. Current polychemotherapeutic protocols based on differentiated and risk-adopted approaches permitted to consider non-Hodgkin’s lymphomas (NHL) potentially curable diseases although they had been considered fatal previously. The aim of this study is to summarize and analyze outcomes of NHL therapy over a 25-year period.

Methods. 246 patients were enrolled in the study. They were treated in the department of chemotherapy of hemoblastoses in the Scientific Research Institute of Pediatric Oncology and Hematology under the NN Blokhin Russian Cancer Research Center over the period of 25 years: from April 1, 1991, till June 1, 2016. B-NHL-BFM 90/95 protocols and a modified B-NHL-BFM 95 protocol (with rituximab) were used for B-cell NHLs (n = 130). Patients with lymphocytic leukemia (n = 75) were treated using ALL-mBFM 90/95 and ALL IC-BFM 2002 protocols. 21 patients with anaplastic large cell lymphomas (ALCL) received treatment according to the B-NHL-BFM 90/95 protocol, and 20 patients received the НИИ ДОГ-АККЛ-2007 protocol.

Results. Taking into account clinical and immunological characteristics of ALCL, the authors invented an original НИИ ДОГ-АККЛ-2007 protocol. Special attention was paid to potential modification of standard treatment regimens for B-cell NHL by adding rituximab. The article demonstrates the evolution in prescription of rituximab for B-cell NHL and possibilities for reduction of the total number of polychemotherapy cycles for late-stage tumors without deterioration of treatment outcomes.

Conclusion. The obtained results permit to conclude that introduction of achievements of oncoimmunology, molecular biology, and cytogenetics will become the basis for further modification of existing treatment options for NHL.


Keywords: Burkitt lymphoma, diffuse large B-cell lymphoma, anaplastic large-cell lymphoma, primary mediastinal (thymic) large B-cell lymphoma, T- and B-cell lymphoblastic lymphomas, treatment, children.

Received: June 12, 2016

Accepted: June 17, 2016

Read in PDF (RUS)pdficon

REFERENCES

  1. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition. Lyon: IARC Press; 2008. pp. 439.
  2. Burkhardt B, Zimmermann M, Oschlies I, et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol. 2005;131(1):39–49. doi: 10.1111/j.1365-2005.05735.x.
  3. Hochberg J, Waxman IM, Kelly KM, et al. Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science. Br J Haematol. 2009;144(1):24–40. doi: 10.1111/j.1365-2008.07393.x.
  4. Baccarani M, Corbelli G, Amadori S, et al. Adolescent and adult lymphoblastic leukemia: prognostic features outcome of therapy. А study of 293 patients. Blood. 1982;60(3):677–84.
  5. Gill PS, Meyer PR, Pavlova Z, et al. B-cell acute lymphoblastic leukemia in adults: clinical, morphologic and immunologic findings. J Clin Oncol. 1986;4(5):737–43.
  6. Bernstein JI, Coleman CN, Strickler JG, et al. Combined modality therapy for adult with small noncleaved cell lymphoma (Burkitt and Burkitt-like type). J Clin Oncol. 1986;4(6):847–58.
  7. Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM-90. Blood. 1999;94(10):3294–306.
  8. Patte C, J. Michon, Frappaz D, et al. Therapy of Burkitt and other B-cell acute lymphoblastic leukaemia and lymphoma: experience with the LMB protocols of the SFOP (French Paediatric Oncology Society) in children and adults. Bail Clin Haematol. 1994;7(2):339–48. doi: 10.1016/s0950-3536(05)80206-
  9. Patte C, Philip T, Rodary C, et al. High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol. 1991;9(1):123–32.
  10. Sun XF, Su YS, Liu DG, et al. Comparing CHOP, CHOP+HD-MTX, and BFM-90 regimens in the survival rate of children and adolescents with B cell non-Hodgkin’s lymphoma. Ai Zheng. 2004;23(8):933–8.
  11. Muller J, Csoka M, Jakab Z, et al. Hungarian experience with non-Hodgkin’s lymphoma in childhood. Magy Onkol. 2006;50(3):253–9.
  12. Cairo MS, Sposto R, Gerrard M, et al. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (³ 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: results of the FAB LMB 96 study. J Clin Oncol. 2012;30(4):387–93. doi: 10.1200/jco.2010.33.3369.
  13. Schwenn M, Blattner S, Lynch E, et al. HiC-COM: a 2-month intensive chemotherapy regimen for children with stage III and IV Burkitt’s lymphoma and B-cell acute lymphoblastic leukemia. J Clin Oncol. 1991;9(1):133–8.
  14. Bowman WP, Shuster JJ, Cook B, et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study. J Clin Oncol. 1996;14(4):1252–61.
  15. Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996;14(3):925–34.
  16. Atra A, Gerrard M, Hobson R, et al. Improved cure rate in children with B-cell acute lymphoblastic leukemia and IV stage B-cell non-Hodgkin lymphoma – results of the UKCCSG 9003 protocol. Br J Cancer. 1998;77(12):2281–5. doi: 10.1038/bjc.1998.379.
  17. Burkhardt B, Oschlies I, Klapper W, et al. Non-Hodgkin’s lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols. Leukemia. 2011;25(1):153–60. doi: 10.1038/leu.2010.245.
  18. Patte C, Auperin A, Michon J, et al. The Societe Francaise d’Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001;97(11):3370–9. doi: 10.1182/blood.v97.11.3370.
  19. Patte C, Auperin A, Gerrard M, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007;109(7):2773–80. doi: 10.1182/blood-2006-07-
  20. Laver JH, Kraveka JM, Hutchison RE, et al. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol. 2005;23(3):541–7. doi: 10.1200/jco.2005.11.075.
  21. Woessmann W, Seidemann K, Mann G.et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2005;105(3):948–58. doi: 10.1182/blood-2004-03-
  22. Gerrard M, Cairo MS, Weston C, et al. Excellent survival following two courses of COPAD chemotherapy. Br J Haematol. 2008;141(6):840–87. doi: 10.1111/j.1365-2008.07144.x.
  23. Seidemann K, Tiemann M, Lauterbach I, et al. Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin-Frankfurt-Munster Group. J Clin Oncol. 2003;21(9):1782–19. doi: 10.1200/jco.2003.08.151.
  24. Akbayram S, Dogan M, Akgun C, et al. Use of rituximab in three children with relapsed/refractory Burkitt lymphoma. Target Oncol. 2010;5(4):291–4. doi: 10.1007/s11523-010-0161-
  25. Okur VF, Oguz A, Karadeniz C, et al. Refractoriness to rituximab monotherapy in a child with relapsed/refractory Burkitt non-Hodgkin lymphoma. Pediatr Hematol Oncol. 2006;23(1):25–31. doi: 10.1080/08880010500313298.
  26. Holmberg LA, Maloney D, Bensinger W. Immunotherapy with rituximab/interleukin-2 after autologous stem cell transplantation as treatment for CD20+ non-Hodgkin’s lymphoma. Clin Lymph Myel. 2006;7(2):135–9. doi: 10.3816/clm.2006.n.051.
  27. Cooney-Qualter E, Krailo M, Angiolillo A.et al. A Phase I Study of 90Yttrium-Ibritumomab-Tiuxetan in Children and Adolescents with Relapsed/Refractory CD20-Positive Non-Hodgkin’s Lymphoma: A Children’s Oncology Group study. Clin Cancer Res. 2007;13(Suppl 18):5652–60. doi: 10.1158/1078-ccr-07-1060.
  28. Richard H, Termuhlen A, Smith L, et al. Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children’s Oncology Group Study A5962. Biol Blood Marrow Transplant. 2011;17(2):249–58. doi: 10.1016/j.bbmt.2010.07.002.
  29. Pinkel D, Johnson W, Aur RJ. Non-Hodgkin’s lymphoma in children. Br J Cancer. 1975;2:298–23.
  30. Wollner N, Exelby PR, Lieberman PH. Non-Hodgkin’s lymphoma in children: a progress report on the original patients treated with the LSA2-L2 protocol. Cancer. 1979;44(6):1990–9. doi: 10.1002/1097-0142(197912)44:6<1990::aid-cncr2820440605>3.0.co;2-
  31. Asselin BL, Devidas M, Wang C, et al. Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children’s Oncology Group (POG 9404). Blood. 2011;118(4):874–83. doi: 10.1182/blood-2010-06-
  32. Wiernik P, Goldman J, Dutcher J. Neoplastic disease of the blood. Cambridge; 1216 p.
  33. Tubergen D, Krailo M, Meadows A, et al. Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin’s lymphoma: a Children’s Cancer Group study. J Clin Oncol Leuk. 1999;13(3):335–42.
  34. Amylon MD, Shuster J, Pullen J, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma; Pediatr Oncol Group study. Leukemia. 1999;13(3):335–42. doi: 1038/sj.leu.2401310.
  35. Patte C, Philip T, Rodary C, et al. Improved survival rate in children with stage III-IV B-cell non-Hodgkin lymphoma and leukemia using multiagent chemotherapy: results of a study of 114 children from the French Pediatric Oncology Society. J Clin Oncol. 1986;4(8):1219–26.
  36. Reiter A, Schrappe M, Ludwig WD, et al. Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group. Blood. 1992;80(10):2471–8.
  37. Reiter A, Schrappe M, Parwaresch R, et al. Non-Hodgkin’s lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage – a report of the Berlin-Frankfurt-Munster Group. J Clin Oncol. 1995;13(2):359–72.
  38. Nachman J, Sather HN, Cherlow JM, et al. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children’s Cancer Group. J Clin Oncol. 1998;16(3):920–30.
  39. Tang JY, Xue HL, Chen J, et al. Multi-center trial based on SCMC-ALL-2005 for children’s acute lymphoblastic leukemia. Zhonghua Er Ke Za Zhi. 2013;51(7):495–501.
  40. Tallen G, Ratei R, Mann G, et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol. 2010;28(14):2339–47. doi: 10.1200/jco.2009.25.1983.
  41. Dunsmore KP, Devidas M, Linda SB, et al. Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group. J Clin Oncol. 2012;30(22):2753–9. doi: 10.1200/jco.2011.40.8724.
  42. Lambe CU, Averett DR, Paff MT, et al. 2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies. Cancer Res. 1995;55(15):3352–6.
  43. Cooper TM, Razzouk BI, Gerbing R, et al. Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2013;60(7):1141–7. doi: 10.1002/pbc.24398.
  44. Schroeder H, Garwicz S, Kristinsson J, et al. Outcome after first relapse in children with acute lymphoblastic leukemia: a population-based study of 315 patients from the Nordic Society of Pediatric Hematology and Oncology (NOPHO). Med Pediatr Oncol. 1995;25(5):372–8. doi: 10.1002/mpo.2950250503.
  45. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favourable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198(6):851–62. doi: 10.1084/jem.20031074.
  46. Borgmann A, von Stackelberg A, Hartmann R, et al. Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis. 2003;101(10):3835–9. doi: 10.1182/blood.v101.10.3835.
  47. Wheeler K, Richards S, Bailey C, et al. Comparison of bone marrow transplant and chemotherapy for relapsed childhood acute lymphoblastic leukaemia: the MRC UKALL X experience. Medical Research Council Working Party on Childhood Leukaemia. Br J Haematol. 1998;101(1):94–103. doi: 10.1046/j.1365-2141.1998.00676.x.
  48. Stein H, Mason DY, Gerdes J, et al. The expression of Hodgkin’s disease associated antigen Ki-1 in reactive and neoplasic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from avtivated lymphoid cells. Blood. 1985;66(4):848–58.
  49. Ferreri AJ, Govi S, Pileri SA, Savage KJ. Anaplastic large cell lymphoma, ALK-negative. Crit Rev Oncol Hematol. 2013;85(2):206–15. doi: 10.1016/j.critrevonc.2012.06.004.
  50. Sibon D, Fournier M, Briere J, et al. Prognostic Factors and Long Term Outcome of 138 Adults with Systemic Anaplastic Large-Cell Lymphoma: a Retrospective Study by the Groupe d’Etude Des Lymphomes De l’Adulte (GELA). Blood. 2010;116: Abstract 322.
  51. Park SJ, Kim S, Lee DH, et al. Primary Systemic Anaplastic Large Cell Lymphoma in Korean Adults: 11 Years’ Experience at Asan Medical Center. Yonsei Med J. 2008;49(4):601–9. doi: 10.3349/ymj.2008.49.4.601.
  52. Wang YF, Yang YL, Gao ZF, et al. Clinical and laboratory characteristics of systemic anaplastic large cell lymphoma in Chinese patients. J Hematol Oncol. 2012;5(1):38. doi: 10.1186/1756-8722-5-38.
  53. Amin HM, Lai R. Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood. 2007;110(7):2259–67. doi: 10.1182/blood-2007-04-060715.
  54. Moreno L, Garzon L, Bautista FJ, et al. Diagnosis of paediatric anaplastic large-cell lymphoma: a historical perspective from a single institution. Clin Transl Oncol. 2009;11(5):318–21. doi: 10.1007/s12094-009-0360-
  55. Le Deley MC, Reiter A, Williams D, et al. Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study. Blood. 2008;111(3):1560–6. doi: 10.1182/blood-2007-07-
  56. Pillon M, Gregucci F, Lombardi A, et al. Results of AIEOP LNH-97 protocol for the treatment of anaplastic large cell lymphoma of childhood. Pediatr Blood Cancer. 2012;59(5):828–33. doi: 10.1002/pbc.24125.
  57. Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood. 1999;93(11):3913–21.
  58. Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral Tcell Lymphoma Project. Blood. 2008;111(12):5496–504. doi: 10.1182/blood-2008-01-
  59. Abramov D, Oschlies I, Zimmermann M, et al. Expression of CD8 is associated with non-common type morphology and outcome in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Haematologica. 2013;98(10):1547–53. doi: 10.3324/haematol.2013.085837.
  60. Damm-Welk C, Mussolin L, Zimmermann M, et al. Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma. Blood. 2014;123(3):334–7. doi: 10.1182/blood-2013-09-
  61. Bonvini P, Gastaldi T, Falini B, et al. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK+ CD30+ lymphoma cells by Hsp90 antagonist 17-allylamino, 17-demethoxygeldanamycin. Cancer Res. 2002;62(5):1559–66.
  62. Ergin M, Denning MF, Izban KF, et al. Inhibition of tyrosine kinase activity induces caspase-dependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein. Exp Hematol. 2001;29(9):1082–90. doi: 10.1016/s0301-472x(01)00688-
  63. Han Y, Amin HM, Franko B, et al. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteasome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma. Blood. 2006;108(8):2796–803. doi: 10.1182/blood-2006-04-
  64. Ogura M, Tobinai K, Hatake K, et al. Phase I/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large-cell lymphoma. Cancer Sci. 2014;105(7):840–6. doi: 10.1111/cas.12435.
  65. Mosse YP, Lim MS, Voss SD, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium study. Lancet Oncol. 2013;14(6):472–80. doi: 10.1016/s1470-2045(13)70095-
  66. Brugieres L, Le Deley MC, Rosolen A, et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: a results of a randomized trial of the EICNHL Group. J Clin Oncol. 2009;27(6):897–903. doi: 10.1200/jco.2008.18.1487.
  67. Seidemann K, Tiemann M, Schrappe M, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood. 2001;97(12):3699–706. doi: 10.1182/blood.v97.12.3699.
  68. Woessmann W, Zimmermann M, Lenhard M, et al. Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: a BFM-group study. J Clin Oncol. 2011;29(22):3065–71. doi: 10.1200/jco.2011.34.8417.
  69. Goldberg JD, Casulo C, Horwitz The role of hematopoietic stem cell transplantation in peripheral T-cell lymphomas. In: Non-Hodgkin Lymphoma Cancer Drug Discovery and Development. Springer; 2013. pp. 279–93. doi: 10.1007/978-1-4614-5851-7_16.
  70. Giulino-Roth L, Ricafort R, Kernan NA, et al. Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation. Pediatr Blood Cancer. 2013;60(12):2018–24. doi: 10.1002/pbc.24722.
  71. Woessmann W, Peters C, Lenhard M. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents – a Berlin-Frankfurt-Munster group report. Br J Haematol. 2006;133(2):176–82. doi: 10.1111/j.1365-2141.2006.06004.x.
  72. Mori T, Takimoto T, Katano N, et al. Recurrent childhood anaplastic large cell lymphoma: a retrospective analysis of registered cases in Japan. Br J Haematol. 2006;132(5):594–7. doi: 10.1111/j.1365-2005.05910.x.
  73. Луговская С.А., Почтарь М.Е., Тупицын Н.Н. Иммунофенотипирование в диагностике гемобластозов. М.: Триада, 2005. 165 с. [Lugovskaya SA, Pochtar’ ME, Tupitsyn NN. Immunofenotipirovanie v diagnostike gemoblastozov. (Immunophenotyping in diagnosis of hemoblastoses.) Moscow: Triada Publ.; 2005. 165 p. (In Russ)]
  74. Курильников А.Я. Мабтера — первые моноклональные антитела в терапии неходжкинских лимфом. Современная онкология. 2002;4(1):25–8. [Kuril’nikov AYa. Mabtera: first monoclonal antibodies in therapy of non-Hodgkin’s lymphomas. Sovremennaya onkologiya. 2002;4(1):25–8. (In Russ)]
  75. Reff M, Carner C, Chambers K, et al. Depletion of B-cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83(2):435–45.
  76. Okur FV, Oguz A, Karadeniz C, et al. Refractoriness to rituximab monotherapy in a child with relapsed/refractory Burkitt non-Hodgkin lymphoma. Pediatr Hematol Oncol. 2006;23(1):25–31. doi: 10.1080/08880010500313298.
  77. Marcus R, Hagenbeek A. The therapeutic use of rituximab in non-Hodgkin’s lymphoma. Eur J Haematol. 2007;78(s67):5–14. doi: 10.1111/j.1600-0609.2006.00789.x.
  78. Plosker GL, Figgitt DP. Rituximab. Drugs. 2003;63(8):803–43. doi: 10.2165/00003495-200363080-
  79. Михайлова Н.Б. Роль ритуксимаба в лечении неходжкинских лимфом (реферативный обзор рандомизированных клинических исследований). Современная онкология. 2009;11(3):28–31. [Mikhailova NB. Role of rituximab in treatment of non-Hodgkin’s lymphomas (abstract review of randomized clinical trials). Sovremennaya onkologiya. 2009;11(3):28–31. (In Russ)]
  80. Li X, Liu Z, Cao J, et al. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group. Ann Hematol. 2012;91(6):837–45. doi: 10.1007/s00277-011-1375-
  81. Thomas DA, Faderl S, O’Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. 2006;106(7):1569–80. doi: 10.1002/cncr.21776.
  82. Fayad L, Thomas D, Romaguera J. Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas. Clin Lymph Myel. 2007;8(2):57–62. doi: 10.3816/clm.2007.s.034.
  83. Meinhardt A, Burkhardt B, Zimmermann M, et al. Phase II Window Study on Rituximab in Newly Diagnosed Pediatric Mature B-Cell Non-Hodgkin’s Lymphoma and Burkitt Leukemia. J Clin Oncol. 2010;28(19):3115–21. doi: 10.1200/jco.2009.26.6791.
  84. Bilic E, Femenic R, Conja J, et al. CD20-positive childhood B-non-Hodgkin lymphoma: morphology, immunophenotype and a novel treatment approach: a single center experience. Coll Antropol. 2010;34(1):171–5.
  85. Смирнова Н.В., Мякова Н.В., Белогурова М.Б. и др. Лечение зрелоклеточных В-клеточных неходжкинских лимфом с использованием комбинированной иммунохимиотерапии: возможности оптимизации терапевтической стратегии. Онкогематология. 2015;10(4):15–24. doi: 10.17650/1818-8346-2015-10-4-15-24. [Smirnova NV, Myakova NV, Belogurova MB, et al. Treatment of B-cells non-Hodgkin lymphomas with combined immunochemotherapy: ability to treatment optimization. Oncohematology. 2015;10(4):15–24. doi: 10.17650/1818-8346-2015-10-4-15-24. (In Russ)]
  86. Miyamoto KI, Kobayashi Y, Maeshima AM, et al. Clinicopathological prognostic factors of 24 patients with B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Int J Hematol. 2016;103(6):693–702. doi: 1007/s12185-016-1989-z.
  87. Gerrard M, Cairo MS, Weston C, et al. Excellent survival following two courses of COPAD chemotherapy. Br J Haematol. 2008;141(6):840–7. doi: 10.1111/j.1365-2008.07144.x.
  88. Patte C, Auperin A, Gerrard M, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007;109(7):2773–80. doi: 10.1182/blood-2006-07-
  89. Stary J, Zimmermann M, Campbell M, et al. Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002. J Clin Oncol. 2014;32(3):174–84. doi: 10.1200/jco.2013.48.6522.